| Title |
Meningococcal Vaccines: Current Issues and Future Strategies
|
|---|---|
| Published in |
Drugs, July 2013
|
| DOI | 10.1007/s40265-013-0079-2 |
| Pubmed ID | |
| Authors |
Amanda C. Cohn, Lee H. Harrison |
| Abstract |
Since the introduction of the first meningococcal conjugate vaccines in 1999, remarkable progress has been made in reducing the morbidity and mortality caused by meningococcal disease. Currently, varying meningococcal conjugate vaccines provide protection against serogroups A, C, Y, and W meningococcal disease. A large impact has been seen after vaccine introduction, particularly in the UK after vaccinating all 1-17 year olds. The introduction of serogroup A conjugate vaccine in the meningitis belt has the potential to control epidemics of disease that disproportionately affect this area of the world. Issues remain that require continued vigilance with disease surveillance and frequent reassessment of vaccine strategies. These issues include duration of protection, potential increases in non-vaccine serogroups, and vaccine safety and potential interference with other routine vaccines. Serogroup B meningococcal vaccines are protein-based vaccines, with the first approved in early 2013. Understanding the potential impact of serogroup B vaccines is critical to developing future meningococcal vaccination strategies. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 3% |
| Unknown | 34 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 23% |
| Student > Bachelor | 7 | 20% |
| Student > Postgraduate | 5 | 14% |
| Student > Master | 3 | 9% |
| Lecturer | 2 | 6% |
| Other | 6 | 17% |
| Unknown | 4 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 34% |
| Agricultural and Biological Sciences | 6 | 17% |
| Nursing and Health Professions | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Computer Science | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 6 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2014.
All research outputs
#4,126,170
of 22,721,584 outputs
Outputs from Drugs
#580
of 3,251 outputs
Outputs of similar age
#35,421
of 194,215 outputs
Outputs of similar age from Drugs
#6
of 29 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,251 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,215 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.